Objective: To clarify the clinical efficacy of Pulmicort combined with Terbutaline atomization in the treatment of mycoplasma pneumonia in children. Methods: A total of 120 pediatric patients with mycoplasma pneumonia admitted to our hospital from January 2017 to December 2020 were included. The ages of all included patients were less than 13 years old. The 120 children were divided into a control group and an observation group using random number method, 60 children in each group. The control group was treated with erythromycin, and the observation group was treated with Pulmicort combined with Terbutaline atomization on this basis. The statuses of symptom improvement between the two groups were observed. Results: There was no statistical difference in gender composition and age between the two groups (P>0.05). Compared with the control group, the symptoms of the observation group were improved more obviously, the duration of symptoms was shorter, and the total effective rate was higher (P>0.05). The incidence of adverse reactions in both groups was low, and there was no statistical difference between the two groups. Conclusion: Pulmicort respules combined with terbutaline atomization is an effective treatment for mycoplasma pneumonia in children, and can be popularized in clinical work.